You are here: Industry Insights > Puma Biotechnology

News List

Puma Biotechnology and Pierre Fabre enter into an exclusive license agreement for the development and marketing of NERLYNX® (neratinib) pharmafocusasia
April 03, 2019
Puma Biotechnology, Inc and Pierre Fabre have entered into an exclusive license agreement under which Pierre Fabre will develop and market NERLYNX® (neratinib) in Europe and in some regions of Africa. In September 2018...
Knight Therapeutics licences cancer drug from Puma Biotechnology pharmaceutical-technology
January 15, 2019
Canada-based Knight Therapeutics signed an exclusive licence agreement with Puma Biotechnology to commercialise Nerlynx (neratinib) medicine in the country.....
Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX (neratinib) in Canada firstwordpharma
January 13, 2019
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that it has entered into an exclusive License Agreement with Knight Therapeutics Inc. (TSX: GUD) that grants Knight the exclusive right to commercialize NERLYNX® (neratinib) i
After making $1M+ on illegal trades, former Puma Biotechnology executive gets prison term fiercepharma
June 25, 2018
Former Puma Biotechnology executive Robert Gadimian made millions during his time at the company, but after illegally trading on insider information, he has returned $1.1 million and been ordered to serve a prison term.